Navigation Links
Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
Date:6/13/2011

d each year and that there were nearly 15,000 deaths from bladder cancer in the United States last year. Bladder cancer is the costliest of all cancers from diagnosis to death. Because bladder cancer has a recurrence rate of 50-80 percent, patients requires life-long monitoring and treatment. Nearly $3 billion is spent in the U.S. alone each year on treatment of bladder cancer.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Urinary Conduit and the Neo-Kidney
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
2. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
7. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
8. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
9. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
10. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... BRIDGEWATER, N.J. , May 5, 2015  CorMedix ... developing and commercializing therapeutic products for the treatment of ... 2015 financial results on May 7.  Randy Milby ... investor conference call on Friday, May 8 at 9:00 ... in the conference call, please call 1-877-407-8031 (U.S.), 1-201-689-8031 ...
(Date:5/5/2015)... 5, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... May 11 th before the open, followed by a ... results and business outlook. Participants should call (888) ... (International) and request the InspireMD call. A live webcast of ...
(Date:5/5/2015)... May 5, 2015 GW Pharmaceuticals plc ... a biopharmaceutical company focused on discovering, developing and ... platform, announced today the closing of the previously ... GW of 1,600,000 American Depositary Shares (ADSs) at ... proceeds of approximately $179.2 million (before deducting underwriting ...
Breaking Medicine Technology:CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4
... Oct. 1 VirtualScopics, Inc. (Nasdaq: VSCP ), ... revenues for the third quarter ended September 30, 2010 exceeded ... comparable period in 2009 and a greater than 9% growth ... increased over 30% for the period ended September 30, 2010 ...
... 1 Palatin Technologies, Inc. (NYSE Amex: PTN ... Annual BIO Investor Forum on Wednesday, October 6, 2010 at ... the 9th Annual BIO Investor Forum will take place October ... Carl Spana, Ph.D., President and Chief Executive Officer ...
Cached Medicine Technology:VirtualScopics Revenues Hit Another Quarterly Record 2VirtualScopics Revenues Hit Another Quarterly Record 3
(Date:5/6/2015)... May 06, 2015 More and more people ... created by Brian Flatt, personal trainer and nutritionist. This particular ... 23 pounds in just three weeks or 21 days. , ... been scientifically tested and found to work on all types ... On average, people lose between 12 and 23 pounds using ...
(Date:5/5/2015)... VA (PRWEB) May 06, 2015 Social ... Regulations, Make Social Media Your Most Powerful Marketing Tool ... – Washington, DC, http://www.fdanews.com/SocialMedia , Social media ... dream of social media’s reach. Patients are using it ... their doctors about what they’ve discovered. , But, it ...
(Date:5/5/2015)... 2015 The Journal of ... “ Priority interventions to improve the management of ... research of the ACCORD program ” , As ... actors, including clinicians, patients and family members, managers, ... which included knowledge gap, “work in silos”, lack ...
(Date:5/5/2015)... FL (PRWEB) May 05, 2015 ... company focused on the $1.6 billion peripheral nerve repair ... first quarter ended March 31, 2015 compared to $3.14 ... market’s continued adoption of our proprietary portfolio of nerve ... Connector and AxoGuard® Nerve Protector – and our solid ...
(Date:5/5/2015)... May 05, 2015 The 2015 Crystal Ball, ... to benefit their global research, outreach and patient advocacy programs. ... and awards ceremony that attracted hundreds of supporters. , The ... discovery of the hepatitis B virus (HBV) by Dr. Baruch ... the Nobel Prize in Medicine for his discovery of the ...
Breaking Medicine News(10 mins):Health News:Brian Flatt Announces The 3 Week Diet - A Scientifically Proven Diet Plan 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3
... More than 600 people will gather for the Consortium ... held at the University of Washington in Seattle on ... in global health. The conference is the largest university-based ... all of the major university-based global health programs in ...
... journal Nature , Miguel Godinho Ferreira, Principal Investigator ... lead a team of researchers to shed light on ... of telomeres, the protective tips of chromosomes: while broken ... or cigarette smoke) are quickly joined together, telomeres are ...
... commonly prescribed to treat adolescent acne can increase attention ... fragile X syndrome, the most common inherited cause of ... is the first published on parents, reports of their ... by researchers at the UC Davis MIND Institute, the ...
... By Ellin Holohan HealthDay Reporter , WEDNESDAY, Sept. ... notion that angioplasty, a common procedure to open clogged arteries, ... a new study shows. In fact, the evidence suggests ... heart patients -- people whose condition has not changed recently ...
... fabrics to keep clothing looking fresh and wrinkle-free is unlikely ... article in the current issue of Chemical & Engineering News ... J. Hanson notes that manufacturers have added formaldehyde to fabrics ... care for, particularly to reduce wrinkling in cotton and prevent ...
... team representing the schools of Medicine, Nursing and Social ... clinical pastoral education programs in three Louisville hospitals, has ... Institutes of Health that will fund the development, implementation ... program. Work related to the project will begin immediately. ...
Cached Medicine News:Health News:University, government and philanthropic leaders converge in Seattle to advance global health 2Health News:University, government and philanthropic leaders converge in Seattle to advance global health 3Health News:Why chromosomes never tie their shoelaces 2Health News:Why chromosomes never tie their shoelaces 3Health News:Parents report a widely prescribed antibiotic is effective for fragile X treatment 2Health News:Parents report a widely prescribed antibiotic is effective for fragile X treatment 3Health News:Parents report a widely prescribed antibiotic is effective for fragile X treatment 4Health News:Many Heart Patients Place False Hope in Angioplasty 2Health News:Many Heart Patients Place False Hope in Angioplasty 3Health News:Grant will aid creation of interdisciplinary oncology palliative care education program 2Health News:Grant will aid creation of interdisciplinary oncology palliative care education program 3
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: